eligibility_summary
Eligible: clear cell RCC, advanced/metastatic, prior ICI and VEGF inhibitor, measurable disease (RECIST 1.1), ≥3w or 5 half-lives since last therapy, KPS ≥70. Exclude: CNS mets/cord compression unless treated, off steroids ≥8w, stable, CNS dysfunction, RT <21d (bone palliation <2w), other active malignancy <24m (except basal/squamous skin or CIS cervix/bladder), gene/engineered/adoptive T-cell therapy <6w, prior CD70 therapy, steroids >5 mg/d, primary immunodef., active autoimmune on immunosuppression.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs/interventions and mechanisms: ADI-270 — engineered Vδ1 γδ CAR-T cell therapy (armored, allogeneic) that uses a chimeric antigen receptor to recognize and kill CD70-expressing tumor cells, Fludarabine — purine analog chemotherapy for lymphodepletion, reducing host lymphocytes to promote CAR-T expansion, Cyclophosphamide — alkylating chemotherapy for lymphodepletion via DNA crosslinking. Cells/pathways targeted: CD70 on clear cell renal cell carcinoma, effector cells are engineered γδ (Vδ1) T cells activating cytotoxicity upon CD70 engagement, lymphodepletion targets host lymphocytes to create “space” and cytokine support for CAR-T engraftment and activity.